ExpreS2ion Biotechnologies

ExpreS2ion Biotechnologies is a Danish biotechnology business situated in Hrsholm, Denmark that specializes in the development of new vaccines and immunotherapy medicines and is listed on the Nasdaq First North Growth Market Sweden.

ExpreS2ion is a member of the PREVENT-nCoV consortium, which also includes AdaptVac (a collaboration between ExpreS2ion Biotechnologies and the University of Copenhagen spin-off NextGen Vaccines), Leiden University Medical Center, the Institute for Tropical Medicine Tübingen, the University of Copenhagen's Department of Immunology and Microbiology (ISIM), and the Laboratory of Virology at Wageningen University and Research. In March 2020, the group was given a €2.7 million EU Horizon 2020 funding for the development of a COVID-19 vaccine candidate, with ExpreS2ion receiving €0.88 million.

ExpreS2ion creates vaccines for diseases such as COVID-19, influenza, and breast cancer using its non-viral Drosophila S2 cells-based expression technology, ExpreS2, which is known for managing even the most difficult protein challenges.

The company also works on other projects, such as many malaria vaccines, and provides protein expression and manufacturing services ranging from discovery to pre-clinical research and cGMP production.

Founded: 2010

Headquarters: Hørsholm, Denmark

Website: https://expres2ionbio.com/